What's Happening?
Soleo Health, a national provider of complex specialty pharmacy services, has been selected as a specialty pharmacy partner for Pasatru™ (garetosmab-grts), Regeneron's FDA-approved product. Pasatru™ is the first and only treatment demonstrated to reduce
the formation of new heterotopic ossification (HO) lesions and clinician-assessed flare-ups in adults with fibrodysplasia ossificans progressiva (FOP), an ultra-rare genetic disorder. The FDA approved Pasatru™ on August 19, 2026. Soleo Health will facilitate patient access to Pasatru™ by collaborating with providers, patient assistance programs, and infusion support services. The company plans to leverage its expertise in ultra-rare diseases through its Soleo-employed nurses and clinical support team to streamline therapy coordination. Drew Walk, chief executive officer of Soleo Health, stated that the addition of Pasatru™ to their SoleoRare® program underscores their commitment to specialized care for the FOP community.
Why It's Important?
This partnership is highly significant for the U.S. healthcare landscape, particularly for the FOP community. Fibrodysplasia Ossificans Progressiva is an extremely rare and debilitating condition, and the approval of Pasatru™ represents a major therapeutic breakthrough. Soleo Health's role as a specialty pharmacy partner ensures that eligible patients will have access to this novel treatment, which is crucial given the complexity of administering such specialized medications. This collaboration highlights the growing importance of specialty pharmacies in managing ultra-rare diseases, where patient support, coordination, and expert clinical care are paramount. The availability of Pasatru™ could dramatically improve the quality of life for FOP patients by reducing the progression of HO lesions, thereby mitigating the severe physical limitations associated with the disease.
What's Next?
Soleo Health will begin implementing its support services to ensure seamless access to Pasatru™ for FOP patients across the U.S. This will involve close coordination with prescribing physicians, insurance providers, and patient advocacy groups to overcome potential barriers to treatment. Regeneron will likely focus on further research and development to enhance FOP treatments and expand the indications for Pasatru™. The success of this partnership could also set a precedent for how other ultra-rare disease treatments are distributed and supported, potentially influencing future collaborations between pharmaceutical companies and specialty pharmacy providers. The FOP community will closely monitor the real-world impact of Pasatru™ on patient outcomes and disease progression.
Beyond the Headlines
The introduction of Pasatru™ for FOP patients underscores the significant advancements in orphan drug development, driven by both scientific innovation and regulatory incentives. However, the high cost often associated with treatments for ultra-rare diseases raises broader questions about healthcare affordability and equitable access. While life-changing for those affected, the economic burden on healthcare systems and individual patients can be substantial. This development also highlights the critical role of patient advocacy groups in driving research and securing access to treatments for conditions that affect small populations. The partnership between Regeneron and Soleo Health exemplifies a model where specialized expertise is crucial for delivering complex therapies, reflecting a trend towards highly personalized and specialized medical care in the U.S.
